The funding round was led by Mercia with backing from Beringea to support private sector expansion and new academy launches.
"These are really exciting times for our business and we are delighted that Mercia have invested in us alongside Beringea to help us scale and support more organisations to deliver a positive contribution to society and the planet. Their investment will allow us to continue to improve and innovate, making it easier for members provide to more social good."
The London based mobile advertising platform has picked up further backing from Mercia to support its international growth.
"At a time when privacy regulation is increasingly limiting the use of personal data, our sophisticated and unique combination of creative, media and AI is leading brand performance on mobile. With this additional investment from Mercia, the next stage of our AI-led platform, offering fully automated capabilities, will provide brands and agencies the chance to translate user attention into profit."
The Yorkshire-based medical technology company secured backing from Mercia and private investors to support production and international expansion.
"The Eventum team have done a massive amount of work in a short space of time in developing Quadsense and getting it approved for clinical use. We are now excited to start scaling up the team to commercialise the product, as well as bringing further innovations to the orthopaedics market."
The Nottingham-based eye care specialist raised the capital from investors including Mercia, Pioneer Group, and the University of Nottingham.
"We are delighted to receive further support from our existing investors. This investment round is an endorsement of our innovative new therapies for ocular care and our commitment to developing a rapid and accessible treatment for the ocular injury. The next stage of development is the scaling of our commercial and operational capabilities ahead of a planned Series A round in late 2023 or early 2024,"
The Swansea-based diagnostics firm secured £1.5m from a syndicate of investors to support product development and clinical trials.
"We’re pleased to have backed CanSense during this investment round with equity support. Their testing technology shows huge potential, with benefits for NHS backlogs if adopted widely, and we’re glad to support the work of this company as it brings its expertise to Wales’ increasingly strong med-tech sector."
